Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06574880 · ClinicalTrials.gov registry record · Phase 1
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
A Phase 1 study of Malignant Neoplasm of Prostate and Locally Advanced Prostate Cancer, sponsored by Angela Y. Jia, MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06574880: Recruiting Phase 1 study of Malignant Neoplasm of Prostate and Locally Advanced Prostate Cancer, sponsored by Angela Y. Jia, MD PhD.
NCT06574880 is a Phase 1 study of Malignant Neoplasm of Prostate and Locally Advanced Prostate Cancer that is actively recruiting participants, run by Angela Y. Jia, MD PhD. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06574880, a Phase 1 study of Malignant Neoplasm of Prostate and Locally Advanced Prostate Cancer, is actively recruiting participants, sponsored by Angela Y. Jia, MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer. Participants will receive one dose of Pluvicto, followed by radiation about 6 weeks later. Radiation therapy will be completed in 5 treatments over the period of 2 weeks. A second dose of Pluvicto will be given 6 weeks after radiation is complete. Some participants may also receive a third dose of Pluvicto, and this would be given 6 weeks after the second dose of Pluvicto.
Primary Outcome
The Phase I goal is to determine the maximally tolerated dose (MTD) of Lu-PSMA-617 when administered with prostate SBRT treatment. The MTD will be captured by analyzing the incidence of dose limiting toxicities occurring within the four weeks after the last dose of treatment.
Conditions Studied
Interventions
- DRUG Lu-PSMA-617
- RADIATION 5-fraction Stereotactic Body Radiation Therapy (SBRT)
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 1 |
What NCT06574880 shows while recruiting
NCT06574880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with Malignant Neoplasm of Prostate appearing as the primary indexed condition, and to 2 interventions - of which Lu-PSMA-617 is the first listed.
NCT06574880 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06574880 about?
NCT06574880 is a clinical study titled "STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer". The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer. Participants w...
What is the current status of trial NCT06574880?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2025-05-13. Estimated completion is 2027-03-01.
What conditions does trial NCT06574880 study?
This clinical trial studies the following conditions: Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer.
What interventions are being tested in trial NCT06574880?
The interventions under investigation include: Lu-PSMA-617 (DRUG), 5-fraction Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT06574880?
This trial is sponsored by Angela Y. Jia, MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06574880 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm of Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06574880's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI